Notch

Neuronal Signaling

Caspase p53 Survivin TNF-alpha MDM2/MDMX Ras IAP Ferroptosis PD-1/PD-L1 ASK Bax/Bak RIP kinase Cyt C Bcl-6 cytohesin Heme Oxygenase OXPHOS Apoptosis related FKBP PKD DAPK Pyroptosis Thymidylate Synthase TRADD TACE Cuproptosis ADAM10 ABC Transporter Annexin A Antifolate Fas/FasL MRP Necroptosis NEDD8 Photosensitizer

All (17)
Notch Inhibitors (14)
Notch Activators (2)
New Notch Products

Cat.No.	Product Name	Information	Product Use Citations
S7169	Crenigacestat (LY3039478)	Crenigacestat (LY3039478) is an oral Notch and gamma-secretase inhibitor with an IC50 of 0.41 nM for Notch.	Cancer Commun (Lond), 2025, 10.1002/cac2.70021 J Exp Clin Cancer Res, 2024, 43(1):286 Cell Death Dis, 2024, 15(1):53
S7399	FLI-06	FLI-06 is a novel inhibitor of Notch signaling with EC50 of 2.3 μM.	Cell Rep Med, 2025, S2666-3791(25)00231-9 Dev Cell, 2022, 57(2):260-276.e9 Autophagy, 2020, 16:1-24
S8280	IMR-1	IMR-1 is a novel class of Notch inhibitors targeting the transcriptional activation with IC50 of 26 μM.	Oncogene, 2024, Cell Death Dis, 2022, 13(11):945 Cell Biosci, 2021, 11(1):87
S9719	Limantrafin (CB-103)	An orally active inhibitor of the Notch transcription activation complex, Limantrafin (CB-103) produces Notch loss-of-function phenotypes in flies and mice and inhibits the growth of human breast cancer and leukemia xenografts.	Sci Rep, 2024, 14(1):21912 Stem Cell Reports, 2023, 18(7):1516-1533 Sci Rep, 2023, 13(1):13700
S3376	RIN1 (RBPJ Inhibitor-1)	RIN1 (RBPJ Inhibitor-1) is a potent inhibitor of the transcription factor RBPJ that disrupts the interaction between NOTCH and RBPJ.	Cell Commun Signal, 2024, 22(1):608 bioRxiv, 2024, 2024.12.02.626505 Nat Cardiovasc Res, 2024, 3(9):1035-1048
S6668	NVS-ZP7-4	NVS-ZP7-4,a Zinc transporter SLC39A7 (ZIP7) inhibitor,is the first reported chemical tool to probe the impact of modulating ER zinc levels and investigate ZIP7 as a novel druggable node in the Notch pathway.
S0225	IMR-1A	IMR-1A, an acid metabolite of IMR-1, is a potent inhibitor of Notch with IC50 of 0.5 μM and Kd of 2.9 μM. This compound exhibits anti-tumor activity.
S2215	DAPT	DAPT is a novel γ-secretase inhibitor, which inhibits Aβ production with IC50 of 20 nM in HEK 293 cells. DAPT enhances the apoptosis of human tongue carcinoma cells and regulates autophagy.	Signal Transduct Target Ther, 2025, 10(1):334 Cell Host Microbe, 2025, 33(3):408-419.e8 Nat Commun, 2025, 16(1):8693
S1575	RO4929097 (RG-4733)	RO4929097 (RG-4733) is a γ secretase inhibitor with IC50 of 4 nM in a cell-free assay, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively. Phase 2.	Nat Commun, 2025, 16(1):10435 Cell Rep Med, 2025, S2666-3791(25)00102-8 Cell Death Dis, 2025, 16(1):150
S2711	DBZ (Dibenzazepine)	DBZ (Dibenzazepine) is a dipeptidic γ-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM in cell-free assays for APPL and Notch cleavage, respectively.	Acta Neuropathol Commun, 2025, 13(1):87 Sci Rep, 2025, 15(1):12154 Nat Commun, 2024, 15(1):9771
S2714	LY411575	LY411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), also inhibits Notch cleavage with IC50 of 0.39 nM in APP or NΔE expressing HEK293 cells. LY411575 induces apoptosis.	Nat Commun, 2025, 16(1):5913 Dev Cell, 2025, S1534-5807(25)00468-X Cell Rep, 2025, 44(4):115508
S1168	Valproic Acid sodium	Valproic Acid sodium is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches. Valproic acid induces Notch1 signaling in small cell lung cancer (SCLC) cells. Valproic acid is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α.	J Exp Clin Cancer Res, 2024, 43(1):152 J Immunother Cancer, 2024, 12(11)e009805 Front Pharmacol, 2024, 15:1534772
S3944	VPA (Valproic acid)	Valproic acid (VPA) is a fatty acid with anticonvulsant properties used in the treatment of epilepsy. It is also a histone deacetylase (HDAC) inhibitor and is under investigation for treatment of HIV and various cancers. This compound induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α. Additionally, it activates Notch-1 signaling.	Cell, 2025, S0092-8674(25)00406-4 Nat Commun, 2025, 16(1):8267 Stem Cell Res Ther, 2025, 16(1):426
S1262	Avagacestat (BMS-708163)	Avagacestat (BMS-708163) is a potent, selective, and orally bioavailable γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 values of 0.3 nM and 0.27 nM, respectively. This compound demonstrates a 193-fold selectivity against Notch and has reached Phase 2 clinical trials.	Nat Commun, 2022, 13(1):6345 Sci Rep, 2022, 12(1):7 Cell, 2021, 184(2):521-533.e14
S1594	Semagacestat (LY450139)	Semagacestat (LY450139) is a γ-secretase blocker for Aβ42, Aβ40 and Aβ38 with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, respectively. It also inhibits Notch signaling with IC50 of 14.1 nM in H4 human glioma cell. This compound has reached Phase 3 clinical trials.	Cell Rep Med, 2025, S2666-3791(25)00102-8 Biochim Biophys Acta Mol Basis Dis, 2025, 1871(8):167992 Cancers (Basel), 2023, 15(6)1883
S0058	Compound E	Compound E (γ-Secretase-IN-1) is a potent inhibitor of γ-secretase, which blocks γ-secretase-mediated cleavage of Notch with an IC50 of 0.32 nM. It also suppresses the production of β-amyloid(40) and β-amyloid(42) with IC50 values of 0.24 nM and 0.37 nM, respectively. It also inhibits Notch signalling, significantly disrupting gonadotropin-dependent follicle growth and halting progression to the preovulatory stage of development.
E6426^New	Sulindac sulfide	Sulindac sulfide is a potent, reversible and noncompetitive inhibitor of γ42-secretase with an IC50 of 20.2 μM. It preferentially reduces Aβ42 generation, inhibits Aβ40 and Notch intracellular domain production, and can be used in Alzheimer's disease research.
S7169	Crenigacestat (LY3039478)	Crenigacestat (LY3039478) is an oral Notch and gamma-secretase inhibitor with an IC50 of 0.41 nM for Notch.	Cancer Commun (Lond), 2025, 10.1002/cac2.70021 J Exp Clin Cancer Res, 2024, 43(1):286 Cell Death Dis, 2024, 15(1):53
S7399	FLI-06	FLI-06 is a novel inhibitor of Notch signaling with EC50 of 2.3 μM.	Cell Rep Med, 2025, S2666-3791(25)00231-9 Dev Cell, 2022, 57(2):260-276.e9 Autophagy, 2020, 16:1-24
S8280	IMR-1	IMR-1 is a novel class of Notch inhibitors targeting the transcriptional activation with IC50 of 26 μM.	Oncogene, 2024, Cell Death Dis, 2022, 13(11):945 Cell Biosci, 2021, 11(1):87
S9719	Limantrafin (CB-103)	An orally active inhibitor of the Notch transcription activation complex, Limantrafin (CB-103) produces Notch loss-of-function phenotypes in flies and mice and inhibits the growth of human breast cancer and leukemia xenografts.	Sci Rep, 2024, 14(1):21912 Stem Cell Reports, 2023, 18(7):1516-1533 Sci Rep, 2023, 13(1):13700
S3376	RIN1 (RBPJ Inhibitor-1)	RIN1 (RBPJ Inhibitor-1) is a potent inhibitor of the transcription factor RBPJ that disrupts the interaction between NOTCH and RBPJ.	Cell Commun Signal, 2024, 22(1):608 bioRxiv, 2024, 2024.12.02.626505 Nat Cardiovasc Res, 2024, 3(9):1035-1048
S0225	IMR-1A	IMR-1A, an acid metabolite of IMR-1, is a potent inhibitor of Notch with IC50 of 0.5 μM and Kd of 2.9 μM. This compound exhibits anti-tumor activity.
S2215	DAPT	DAPT is a novel γ-secretase inhibitor, which inhibits Aβ production with IC50 of 20 nM in HEK 293 cells. DAPT enhances the apoptosis of human tongue carcinoma cells and regulates autophagy.	Signal Transduct Target Ther, 2025, 10(1):334 Cell Host Microbe, 2025, 33(3):408-419.e8 Nat Commun, 2025, 16(1):8693
S1575	RO4929097 (RG-4733)	RO4929097 (RG-4733) is a γ secretase inhibitor with IC50 of 4 nM in a cell-free assay, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively. Phase 2.	Nat Commun, 2025, 16(1):10435 Cell Rep Med, 2025, S2666-3791(25)00102-8 Cell Death Dis, 2025, 16(1):150
S2711	DBZ (Dibenzazepine)	DBZ (Dibenzazepine) is a dipeptidic γ-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM in cell-free assays for APPL and Notch cleavage, respectively.	Acta Neuropathol Commun, 2025, 13(1):87 Sci Rep, 2025, 15(1):12154 Nat Commun, 2024, 15(1):9771
S2714	LY411575	LY411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), also inhibits Notch cleavage with IC50 of 0.39 nM in APP or NΔE expressing HEK293 cells. LY411575 induces apoptosis.	Nat Commun, 2025, 16(1):5913 Dev Cell, 2025, S1534-5807(25)00468-X Cell Rep, 2025, 44(4):115508
S1262	Avagacestat (BMS-708163)	Avagacestat (BMS-708163) is a potent, selective, and orally bioavailable γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 values of 0.3 nM and 0.27 nM, respectively. This compound demonstrates a 193-fold selectivity against Notch and has reached Phase 2 clinical trials.	Nat Commun, 2022, 13(1):6345 Sci Rep, 2022, 12(1):7 Cell, 2021, 184(2):521-533.e14
S1594	Semagacestat (LY450139)	Semagacestat (LY450139) is a γ-secretase blocker for Aβ42, Aβ40 and Aβ38 with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, respectively. It also inhibits Notch signaling with IC50 of 14.1 nM in H4 human glioma cell. This compound has reached Phase 3 clinical trials.	Cell Rep Med, 2025, S2666-3791(25)00102-8 Biochim Biophys Acta Mol Basis Dis, 2025, 1871(8):167992 Cancers (Basel), 2023, 15(6)1883
S0058	Compound E	Compound E (γ-Secretase-IN-1) is a potent inhibitor of γ-secretase, which blocks γ-secretase-mediated cleavage of Notch with an IC50 of 0.32 nM. It also suppresses the production of β-amyloid(40) and β-amyloid(42) with IC50 values of 0.24 nM and 0.37 nM, respectively. It also inhibits Notch signalling, significantly disrupting gonadotropin-dependent follicle growth and halting progression to the preovulatory stage of development.
E6426^New	Sulindac sulfide	Sulindac sulfide is a potent, reversible and noncompetitive inhibitor of γ42-secretase with an IC50 of 20.2 μM. It preferentially reduces Aβ42 generation, inhibits Aβ40 and Notch intracellular domain production, and can be used in Alzheimer's disease research.
S1168	Valproic Acid sodium	Valproic Acid sodium is a HDAC inhibitor by selectively inducing proteasomal degradation of HDAC2, used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches. Valproic acid induces Notch1 signaling in small cell lung cancer (SCLC) cells. Valproic acid is under investigation for treatment of HIV and various cancers. Valproic acid (VPA) induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α.	J Exp Clin Cancer Res, 2024, 43(1):152 J Immunother Cancer, 2024, 12(11)e009805 Front Pharmacol, 2024, 15:1534772
S3944	VPA (Valproic acid)	Valproic acid (VPA) is a fatty acid with anticonvulsant properties used in the treatment of epilepsy. It is also a histone deacetylase (HDAC) inhibitor and is under investigation for treatment of HIV and various cancers. This compound induces autophagy and mitophagy by upregulation of BNIP3 and mitochondrial biogenesis by upregulating PGC-1α. Additionally, it activates Notch-1 signaling.	Cell, 2025, S0092-8674(25)00406-4 Nat Commun, 2025, 16(1):8267 Stem Cell Res Ther, 2025, 16(1):426
E6426^New	Sulindac sulfide	Sulindac sulfide is a potent, reversible and noncompetitive inhibitor of γ42-secretase with an IC50 of 20.2 μM. It preferentially reduces Aβ42 generation, inhibits Aβ40 and Notch intracellular domain production, and can be used in Alzheimer's disease research.